1′substituted carba-nucleoside analogs for antiviral treatment
US8318682B2 · kind B2 · utility
95Cited by
8References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2011 |
| Grant date | Nov 27, 2012 |
| Priority date | — |
| Expiry date | Aug 2, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted with a cyano group. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.